Katie Seitz Evans, President, Product & Operations of Magnite, Inc., filed a Form 4 on September 10, 2026, disclosing the exercise of stock options and the sale of common stock on September 8 and 9, 2026, pursuant to a Rule 10b5-1 trading plan.
A Form 4 filed on September 10, 2026 discloses that Charles Lacey Compton III, Chief Executive Officer and Director of Fastly, Inc. (NASDAQ:FSLY), sold 2,436 shares of Class A Common Stock on September 8, 2026 under a pre-established Rule 10b5-1 trading plan.
Saurabh Sinha, Chief Financial Officer of Arteris, Inc. (NASDAQ:AIP), filed a Form 4 on September 10, 2026, disclosing the acquisition of 142,835 restricted stock units on September 8, 2026, at a price of $0.00.
David H. Wang, a director, officer, and 10% owner of ACM Research, Inc. (NASDAQ:ACMR), filed a Form 4 on September 10, 2026, disclosing stock option exercises and open-market sales of Class A Common Stock on September 8 and September 9, 2026, pursuant to a …
United Parks & Resorts Inc. Chief Executive Officer Marc Swanson disclosed a change in beneficial ownership of common stock in a Form 4 filed with the SEC on September 10, 2026, reporting a transaction dated June 30, 2026.
Guardian Pharmacy Services, Inc. filed a Form 8-K on September 10, 2026, disclosing that it entered into lock-up agreements on that same date with its founders, executive officers, and certain other employees covering approximately 29.9 million shares of Class A common stock.
Stefan J. Murry, Chief Financial Officer of Applied Optoelectronics, Inc., filed a Form 4 on September 10, 2026, reporting the sale of 4,000 shares of common stock on that same date pursuant to a pre-established Rule 10b5-1 trading plan.
A Form 4 filed on September 10, 2026 discloses that Hung-Lun (Fred) Chang, Senior Vice President and North America General Manager of Applied Optoelectronics, Inc. (NASDAQ:AAOI), sold 32,172 shares of common stock on September 8, 2026.
Applied Optoelectronics, Inc. filed a Form 8-K with the SEC on September 10, 2026, disclosing that it entered into and closed a Purchase and Sale Agreement on September 4, 2026, to acquire a commercial property in Houston, Texas for approximately $26,783,472.00 in cash.
Tarsus Pharmaceuticals, Inc. filed a Form 8-K on September 10, 2026, reporting the completion of its acquisition of Alkeus Pharmaceuticals, Inc. on September 4, 2026, pursuant to an Agreement and Plan of Merger dated July 31, 2026.